Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $47.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective hoisted by HC Wainwright from $35.00 to $47.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

STOK has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Chardan Capital started coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Trading Down 9.1 %

NASDAQ:STOK opened at $9.71 on Tuesday. The firm has a market cap of $514.34 million, a P/E ratio of -4.62 and a beta of 0.95. The stock’s 50 day simple moving average is $10.84 and its 200-day simple moving average is $12.40. Stoke Therapeutics has a 12-month low of $5.14 and a 12-month high of $17.58.

Insider Activity at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the transaction, the chief executive officer now directly owns 61,885 shares in the company, valued at approximately $803,886.15. This trade represents a 9.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock worth $809,421 in the last three months. 11.30% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after buying an additional 471,240 shares during the period. Baker BROS. Advisors LP boosted its position in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after buying an additional 265,395 shares during the period. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics in the fourth quarter worth $35,001,000. State Street Corp boosted its position in shares of Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after buying an additional 38,446 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.